Israeli biopharmaceutical company BiondVax Pharmaceuticals has announced positive results from Phase I/II clinical trials of the company’s Multimeric-001 Universal Flu Vaccine.

During the trial in 60 participants BiondVax established that the antibodies generated by the vaccine specifically identified several strains of influenza, including the swine flu strain.

The trial established that the Multimeric-001 Universal Flu Vaccine activated two arms of the human immune system, the humoral (antibody) arm and the cellular arm, which distinguishes the vaccine from existing seasonal flu vaccines, which target the antibody response.

BiondVax CEO Dr Ron Babecoff said that this initial proof of immunogenicity and safety is an important milestone towards ensuring protection against all flu strains through the use of a single vaccine.

“Such a vaccine is expected to do away with the need for annual vaccinations every year as required by existing vaccines,” Babecoff said.

The clinical trial results also showed that BiondVax’s Multimeric-001 Universal Flu Vaccine was safe to use at all doses tested, with and without adjuvant.

The trial is the first of two Phase I/II clinical trials, the second of which has already begun with 60 participants aged 55–75, and is expected to be completed early in 2010.